LeadIQ logo
Learn more at LeadIQ.com

Insights

Expanding Therapeutic Scope Spur Therapeutics is transitioning from rare diseases to more widespread conditions like Parkinson's, dementia, and cardiovascular diseases, presenting an opportunity to target a broader market with potential therapies that address prevalent health issues.

Strategic Funding Position With a revenue range of $10M to $50M and recent funding of $50M, Spur Therapeutics has financial stability that can support sales initiatives and partnerships for the development and commercialization of innovative therapies.

Clinical Success Stories The success of Spur Therapeutics' potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN) serves as compelling case studies to showcase the effectiveness and impact of the company's products, facilitating discussions with potential collaborators and investors.

Competitive Landscape Analysis Understanding the industry landscape and key players like Inozyme Pharma, Repare Therapeutics, and CytomX Therapeutics can provide insights into market positioning, competitive advantages, and potential areas for differentiation for Spur Therapeutics to leverage sales strategies effectively.

Genetic Medicine Innovations By focusing on genetic expression and targeted delivery in therapy development, Spur Therapeutics is at the forefront of genetic medicine advancements, offering a unique selling point that can attract interest from stakeholders looking for cutting-edge solutions in the biotechnology sector.

Similar companies to Spur Therapeutics

Spur Therapeutics Tech Stack

Media & News

Spur Therapeutics's Email Address Formats

Spur Therapeutics uses at least 2 format(s):
Spur Therapeutics Email FormatsExamplePercentage
First.Last@freeline.lifeJohn.Doe@freeline.life
97%
First.Middle@freeline.lifeJohn.Michael@freeline.life
1%
Last@freeline.lifeDoe@freeline.life
1%
FirstMiddle.Last@freeline.lifeJohnMichael.Doe@freeline.life
1%

Frequently Asked Questions

Where is Spur Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Spur Therapeutics's main headquarters is located at Gunnels Wood Road Stevenage, England GB. The company has employees across 6 continents, including AsiaEuropeNorth America.

What is Spur Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Spur Therapeutics's official website is spurtherapeutics.com and has social profiles on LinkedIn.

How much revenue does Spur Therapeutics generate?

Minus sign iconPlus sign icon
As of August 2024, Spur Therapeutics's annual revenue reached $35M.

What is Spur Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Spur Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Spur Therapeutics have currently?

Minus sign iconPlus sign icon
As of August 2024, Spur Therapeutics has approximately 329 employees across 6 continents, including AsiaEuropeNorth America. Key team members include Chief Executive Officer: M. P.Chief Financial Officer: P. S.Chief Scientific Officer: H. S.. Explore Spur Therapeutics's employee directory with LeadIQ.

What industry does Spur Therapeutics belong to?

Minus sign iconPlus sign icon
Spur Therapeutics operates in the Biotechnology Research industry.

What is Spur Therapeutics's email format?

Minus sign iconPlus sign icon
Spur Therapeutics's email format typically follows the pattern of . Find more Spur Therapeutics email formats with LeadIQ.

How much funding has Spur Therapeutics raised to date?

Minus sign iconPlus sign icon
As of August 2024, Spur Therapeutics has raised $50M in funding. The last funding round occurred on Jun 17, 2024 for $50M.

When was Spur Therapeutics founded?

Minus sign iconPlus sign icon
Spur Therapeutics was founded in 2015.
Spur Therapeutics

Spur Therapeutics

Biotechnology ResearchEngland, United Kingdom201-500 Employees

Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. 

Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. 

Toward life-changing therapies, and brighter futures.  
Toward More™ 

Section iconCompany Overview

Headquarters
Gunnels Wood Road Stevenage, England GB
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
201-500

Section iconMedia & News

Section iconFunding & Financials

  • $50M

    Spur Therapeutics has raised a total of $50M of funding over 1 rounds. Their latest funding round was raised on Jun 17, 2024 in the amount of $50M.

  • $10M$50M

    Spur Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $50M

    Spur Therapeutics has raised a total of $50M of funding over 1 rounds. Their latest funding round was raised on Jun 17, 2024 in the amount of $50M.

  • $10M$50M

    Spur Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.